Nivestym Shortage Update: What Patients Need to Know in 2026

For patients prescribed Nivestym (filgrastim-aafi) to support them through cancer treatment, access issues can feel urgent — because they are. If you're wondering whether Nivestym is in shortage and what you should know in 2026, this article has the current picture.

Is There an Active Nivestym Shortage in 2026?

As of 2026, Nivestym is not on the FDA's official drug shortage list. This is an important distinction: a formal shortage means the FDA has identified a critical supply-demand imbalance that threatens patient access nationally. Nivestym has not reached that threshold.

However, "no shortage" does not mean "always easy to find." Many patients are still experiencing real access barriers — and understanding why can help you navigate them more effectively.

Why Nivestym Can Still Be Hard to Find Despite No Formal Shortage

Even without an FDA-declared shortage, several structural factors contribute to access challenges:

• Specialty medication distribution. Nivestym is a biologic requiring refrigeration. It's not a medication most retail pharmacies stock routinely — they typically order it when needed.
• Prior authorization delays. Insurance plans require PA for Nivestym. Even when the medication is available, insurance reviews can create days of delay.
• Formulary competition. With multiple filgrastim biosimilars on the market (Zarxio, Releuko, Nypozi, and Granix), some insurance plans prefer or require a specific product. If Nivestym isn't on your plan's preferred tier, coverage may be denied or require step therapy.
• Localized demand spikes. Cancer treatment centers can see surges in demand around chemotherapy cycle dates, temporarily depleting local inventory.

Historical Context: G-CSF Shortages

The filgrastim class has experienced supply disruptions in the past. The original Neupogen has appeared on the FDA shortage list at various points over the years — most commonly due to manufacturing issues or increased demand during periods when alternative G-CSF products were also under stress. The arrival of biosimilars like Nivestym, Zarxio, Releuko, and Nypozi has helped diversify the supply chain, making nationwide G-CSF shortages less likely today than they were a decade ago.

That said, individual patients can still face access challenges based on their local market and insurance coverage.

What Should Patients Do If They Can't Find Nivestym?

If you're having trouble filling your Nivestym prescription, here are immediate steps:

1. Contact your oncologist's office immediately. Your cancer care team has protocols for medication access issues and can escalate urgent needs.
2. Ask about an alternative biosimilar. Zarxio, Releuko, or Nypozi work similarly. If your doctor agrees, a prescription switch can often happen the same day.
3. Check specialty pharmacies. CVS Specialty, Walgreens Specialty, Accredo, and hospital-affiliated pharmacies are your best bets for specialty biologic stock.
4. Request urgent prior authorization. If a PA is pending, ask your oncologist's office to submit an expedited or urgent review. Most insurers have expedited PA processes for oncology medications.
5. Contact Pfizer Oncology Together. Pfizer's support program (1-800-505-4426) can help with insurance issues and connect patients to assistance resources.

How medfinder Can Help

medfinder is a service that calls pharmacies near you to check which ones can fill your Nivestym prescription. Rather than spending hours on hold, you provide your medication details and location, and medfinder does the calling. Results are texted to you. Visit medfinder.com to get started, or see our full guide on how to find Nivestym in stock near you for more steps.

The Bottom Line for 2026

Nivestym is not in an active FDA shortage as of 2026. The challenges patients face are structural — specialty distribution, prior authorization requirements, and formulary competition — rather than a true supply crisis. By knowing how to navigate the system and who to call, most patients can access the medication they need.